Frontlight ResearchEarly access
CompletedPhase 4
Glucocorticoids for Post-operative Patients With Acute Type A Aortic Dissection (The GLAD Trial)
Key facts
- Who runs it
- Shanghai Zhongshan Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 212 people enrolled
- Started
- 7 Feb 2022
- Ended
- 29 Nov 2023
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Methylprednisolone Injection
- Record updated
- 26 December 2023
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Informed consent
- Age above 18 years old (including 18 years old), regardless of gender
- Confirmed type A aortic dissection with computer tomography and received surgical intervention
- Life expectancy > 3 days after surgery
Who cannot take part
- Glucocorticoid or any other anti-inflammatory drug usage in the past 14 days
- Patients with pre-operative renal insufficiency (patients receiving renal replacement therapy before surgery)
- History of cardiac surgery within the past 3 months or possible iatrogenic aortic dissection
- Bacterial or fungal infection in the past 30 days
- Allergic to glucocorticoid
- Patients diagnosed with malignant tumor undergoing chemotherapy and immunotherapy
- Pregnant
- Implantation of ICD or permanent pacemaker
- Patients with pre-operative severe liver dysfunction (CTP grade C)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is designed to evaluate the effects of glucocorticoid(GC) on improving post-operative organ dysfunction in patients with acute type A aortic dissection(aTAAD). Subjects with confirmed diagnosis of aTAAD undergoing surgical treatment will be enrolled and 1:1 randomly assigned to receive either glucocorticoids or normal treatment. All patients in the glucocorticoids group will be given methylprednisolone intravenously for 3 days after enrollment. The primary endpoint will be the amplitude of variation of Sequential Organ Failure Assessment score on post-operative day 4 compared to baseline.
The 2 groups in the trial
- Glucocorticoid groupTreatment being tested
Treatment: Methylprednisolone Injection
- Control GroupNo study treatment, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Assessment of the Efficacy of Glucocorticoids in Improving Post-operative Organ Dysfunction in Patients With Acute Type A Aortic Dissection(GLAD): a Randomized Controlled Trial
- Record updated
- 26 December 2023